Refusal

Quick links to important sections

Refusal

Treatment option: Alcoholism

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Refusal

Quick Facts

Property Description
Active ingredient Disulfiram ( C10H20N2S4 )
Form Oral Tablet
Pharmacological class Aldehyde Dehydrogenase Inhibitor
General purpose Aid in alcohol abstinence
Origin Synthetic Compound

What Type of Medicine is Refusal (Disulfiram)?

Refusal is a prescription-only medication whose active ingredient is the synthetic compound known as Disulfiram. This medicine is categorized pharmacologically as an Aldehyde Dehydrogenase Inhibitor, placing it within the broader class of anti-alcoholic agents. The drug's mechanism is clinically recognized for establishing a behavioral deterrent against alcohol use. Its identity is defined by its use in providing pharmacological support for the management of chronic alcohol dependence, such as in a typical scenario where a patient commits to long-term sobriety.

The chemical designation for the active substance is Tetraethylthiuram disulfide. Disulfiram is classified as an Essential Medicine, underscoring its recognized importance in global public health systems.

Composition, Origin, and Pharmaceutical Form

The medicine is manufactured as a single-ingredient product supplied for oral ingestion in the solid Tablet dosage form. The function of Refusal is derived exclusively from the chemical properties of Disulfiram, which is an entirely synthetic compound created through chemical synthesis rather than being naturally derived.

This oral preparation is a simple, unflavored tablet, designed specifically for consistent and reliable daily intake. The choice of the tablet form provides a stable, measured platform for administering the active compound, which is essential for maintaining the continuous enzymatic effect required for the deterrent to function.

General Purpose and Mechanism Principle

The overall purpose of Refusal is to aid patients in maintaining abstinence from alcohol by creating a chemical deterrent. This function is achieved by directly interfering with the body’s specific pathway for ethanol metabolism.

As an Aldehyde Dehydrogenase Inhibitor, the drug blocks the enzyme ALDH, which is crucial for breaking down the toxic intermediate product of alcohol metabolism, acetaldehyde. This specific inhibition leads to the rapid acetaldehyde accumulation within the bloodstream, a physiological action designed to reinforce the patient's commitment to avoiding the consumption of alcoholic beverages.

Regulatory References

  1. National Institutes of Health

What side effects are possible with Refusal?

Possible Side Effects and Safety Information

The safety profile of Refusal (Disulfiram) is defined by the severe and potentially life-threatening Disulfiram-Alcohol Reaction (DAR), which is a predictable consequence of ingesting alcohol in any form while taking the medication. DAR symptoms, as documented in official regulatory sources, can include flushing, throbbing headache, respiratory difficulty, chest pain, hypotension, syncope, and, in severe cases, cardiovascular collapse, convulsions, and death.


Adverse reactions unrelated to alcohol ingestion are primarily categorized by System-Organ Class. Serious adverse events include potential Hepatotoxicity and Neurotoxicity.

  • Hepatobiliary Disorders: Severe and sometimes fatal Hepatitis and Hepatic Failure have been reported, sometimes developing even after several months of use. Liver function monitoring is required before and periodically during treatment.
  • Nervous System Disorders: Reactions documented include Peripheral Neuritis, Polyneuropathy, Encephalopathy, and Optic Neuritis, which may lead to vision loss.
  • Psychiatric Disorders: Psychotic reactions, depression, and paranoia are among the reported effects.

Safety Patterns and Restrictions

Some adverse reactions, such as mild drowsiness, fatigability, headache, and a metallic or garlic-like aftertaste, are often transient and may occur primarily during the first two weeks of therapy. However, the risk of a DAR persists for up to 14 days after the last dose is taken.

Official labeling lists safety constraints (contraindications) and cautions for specific populations. The medicine is contraindicated in individuals with severe liver disease, psychoses, severe myocardial disease, or those recently treated with Metronidazole or Paraldehyde. Caution is also advised for patients with pre-existing conditions such as diabetes mellitus or epilepsy.

Overdose and Emergency Response

Overdose with Disulfiram may lead to an exacerbation of known clinical effects, primarily affecting the central nervous system (CNS) and the cardiovascular system. Documented manifestations of overdose include profound CNS depression, presenting as drowsiness, lethargy, mental confusion, or coma. Neurological findings can also include ataxia (loss of coordination) and other movement disorders. Severe outcomes noted in regulatory documents include convulsions, respiratory depression, and cardiovascular collapse. Toxicity has been documented in children following ingestion of 2.5 g or more, with symptoms potentially appearing with a delayed onset, sometimes days after exposure.


When to Seek Help

Due to the severity of documented outcomes and the potential for delayed clinical deterioration, immediate medical attention is required for any suspected overdose. The prescribing information instructs patients to contact a physician or a Poison Control Center immediately. Urgent help from emergency services must be sought if the individual collapses, has trouble breathing, or experiences a seizure.

Officially Documented Management

It is officially stated that no specific antidote is known for Disulfiram overdose. Treatment is restricted to symptomatic and supportive measures, which may include procedures like gastric lavage or the administration of activated charcoal. Intensive observation and monitoring are recommended during post-overdose care to manage severe symptoms and observe for delayed complications.

Therapeutic Uses of Refusal

What Refusal Treats: Main Uses and Benefits

Refusal is commonly used to help with the management of chronic alcohol dependence and Alcohol Use Disorder (AUD). It plays a role in managing symptoms that interfere with daily functioning and supports individuals working toward achieving continuous abstinence. It is recognized as a support mechanism for recovery.


Therapeutic Support for Continuous Abstinence

The medication is commonly used to provide supportive management within the clinical context of chronic alcohol dependence and Alcohol Use Disorder (AUD). It plays a role in managing the long-term pattern of dependency and is applied when appropriate to support individuals maintaining continuous abstinence from alcohol, a goal that assists with managing symptoms that create noticeable physiological strain. The primary practical benefit of Refusal is establishing a pharmacological deterrent that may assist with managing the impulsive behaviors and cravings associated with high relapse risk.


Clinical Context and Patient Benefit

Refusal is commonly used within clinical settings that involve a comprehensive recovery program. The common therapeutic indications include support for Alcohol Use Disorder (AUD), chronic alcohol dependence, and managing the risk of relapse within a structured recovery environment. This support helps ease the overall symptom burden, supports the patient during difficult episodes, and contributes to improved comfort during the maintenance of long-term sobriety.


Quick Fact: Support for Impulsive Behaviors
Refusal provides support by establishing a deterrent that may assist with managing the impulsive behaviors and cravings relevant to the effort to maintain long-term abstinence.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Refusal (Disulfiram)

Official regulatory documents define strict eligibility criteria for Refusal based on patient health status and concurrent substance use. The medicine is primarily approved for adults and co-operative adolescents committed to abstinence from alcohol, provided they have been alcohol-free for at least 12–24 hours prior to initiation.


Absolute Contraindications

Refusal is contraindicated (must not be used) in several populations. This includes patients with severe myocardial disease or coronary occlusion, psychoses (manifest psychoses), or known hypersensitivity to disulfiram or related thiuram derivatives. It is also absolutely prohibited for patients taking or having recently taken metronidazole, paraldehyde, or any alcohol-containing preparation.


Restricted and Special Populations

Population Group Regulatory Status
Pediatric Patients Safety and effectiveness have not been established. Use is not recommended [Source 1.5, 2.3].
Hepatic/Renal Impairment Requires extreme caution due to risk of liver injury; restrictions apply to advanced hepatic/renal disease [Source 1.7, 2.6].
Pregnancy/Lactation Lacks established safety in pregnancy and is not recommended during breastfeeding [Source 1.6, 2.4].
Other Conditions Requires extreme caution in patients with conditions like diabetes mellitus, hypothyroidism, or epilepsy [Source 1.7].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Interaction Restrictions

The primary, mandatory interaction constraint is the absolute prohibition of ethanol (alcohol) in all forms, including ingestible or topical products (e.g., mouthwash, aftershave), due to the risk of a severe Disulfiram-Alcohol Reaction (DAR). This restriction applies for up to 14 days after stopping treatment with Refusal. Regulatory documents also classify co-administration with Metronidazole and Paraldehyde as strictly contraindicated because of the risk of acute psychoses, confusion, or heightened toxicity.


Pharmacokinetic and Exposure Effects

Refusal is officially documented as an inhibitor of specific hepatic enzymes, including CYP2C9 and CYP2E1, which may decrease the metabolic clearance of certain co-administered medicines. This pharmacokinetic interaction can lead to increased plasma concentrations of co-medications. Consequently, official labeling mandates monitoring for drugs such as Phenytoin and Oral Anticoagulants (Warfarin), where Disulfiram may prolong prothrombin time or increase serum levels.


Pharmacodynamic and Additive Effects

Refusal can exhibit additive effects with other Central Nervous System (CNS) depressants, potentially increasing the risk of drowsiness. For co-administration with Isoniazid, regulatory information advises observation for signs of unsteady gait or changes in mental status. The Theophylline metabolism may also be inhibited, resulting in increased serum exposure.

Mechanism of Action

Irreversible Blockade of Alcohol Metabolism

The drug's primary mechanism is the irreversible inhibition of the Aldehyde Dehydrogenase (ALDH) enzyme, which is responsible for the crucial second step in the oxidation of the intermediate acetaldehyde. This covalent binding permanently inactivates the enzyme, fundamentally disrupting the normal Ethanol Metabolism Pathway and resulting in a conditional physiological response.

Acute Systemic Acetaldehyde-Mediated Response

When ethanol is subsequently consumed, the acetaldehyde that forms cannot be broken down, leading to its rapid and dramatic accumulation in the blood and tissues. This high concentration of the toxic metabolite triggers an acute systemic response characterized by significant cardiovascular and autonomic changes, including profound vasodilation, tachycardia, and hypotension, which are the direct consequences of the chemical buildup.

Conditional and Peripheral Mechanistic Constraint

The entire physiological outcome is conditional upon the subsequent introduction of ethanol to the system. While the enzyme blockade is constant, the intense systemic effects only manifest following alcohol consumption, resulting in a predictable, pronounced peripheral physiological response rather than an action that directly modulates the underlying central neural pathways of dependence.

Dosage and Administration Information

How to Use Refusal (Disulfiram) – Administration Guidelines

Refusal, whose active ingredient is Disulfiram, is administered solely via the oral route in tablet form. Its usage protocol is strictly defined, focusing on continuous administration and proper preparation.

Standard Dosing and Frequency

Administration begins with an initial dose phase, typically up to 500 mg once daily, which is maintained for one to two weeks. The subsequent maintenance dose is commonly 250 mg daily, though the labeled range permits doses between 125 mg and 500 mg once per day. Regional schedules may vary, including the use of a twice-weekly regimen or a higher initial dose for the first few days. The medication is usually taken once daily and may be administered in the morning or, if sedation occurs, at bedtime.

Administration Conditions and Duration

Refusal therapy requires a foundational condition: the patient must have achieved at least 12 hours of verifiable alcohol abstinence before the first dose is administered. To ensure consistent intake, particularly in supervised settings, the tablets may be crushed and mixed with liquid. The treatment is fundamentally long-term and is continued until a stable basis for self-control has been established.

Population-Specific Usage
Older Adults Dose selection should be cautious, often starting at the low end of the recommended range.
Pediatric Patients Use in children is not recommended.

Recent Clinical Evidence

Research evidence / Overview of studies for Refusal

Evidence for Use in Alcohol Use Disorder (AUD)

Research exploring the use of Refusal centers primarily on its evaluation in adults diagnosed with Alcohol Use Disorder (AUD) who are seeking to maintain abstinence from alcohol. The research landscape mainly includes Randomized Controlled Trials (RCTs), along with Systematic Reviews and Meta-analyses that pool data from multiple trials. These studies were designed to measure continuous abstinence from alcohol, the time to first relapse, and changes in the overall frequency of drinking episodes.

Findings describe patterns observed in these studies, which often varied depending on the conditions of the trial. Studies monitored how outcomes evolved in the observed populations, with some trials describing measurements related to changes in abstinence status, especially in situations where the medication intake was supervised. However, results applied only to the populations studied, and findings were mixed when comparing results from fully blinded, placebo-controlled trials. This difference in observed patterns highlights the potential influence of psychological and behavioral factors on the overall outcome.


Clinical Research on Co-occurring Conditions

Refusal was evaluated in research exploring its role alongside other measures in patients who have both Alcohol Use Disorder and Cocaine Dependence. The research in this area is more limited and includes a small number of Randomized Controlled Trials. These studies explored outcomes related to the overall frequency of cocaine use and examined patient-reported outcomes describing perceived discomfort related to cocaine craving. Research exploring short-term changes in this co-occurring population is still considered emerging. Data show patterns related to a potential change in cocaine use frequency in some studies, but evidence is limited overall, and certainty remains low.


Long-Term Research and Durability of Findings

The majority of the initial research focused on evaluating outcomes over short-term follow-up durations, typically ranging up to three to six months. Studies monitored responses over defined time intervals. While some meta-analyses include data points extending out to 12 months, long-term effects are not fully established regarding the sustained pattern of effect over extended time periods (beyond six months). There is limited information for long-term outcomes, meaning that the sustained pattern of effect beyond the first year is an area where research is still ongoing.


Consistency and Gaps in the Evidence

The evidence base for Refusal, while extensive for its main use, has certain key limitations that scientists and regulators often discuss. A major point of discussion is the inconsistency of findings reported across different types of controlled trials. This variability in evidence quality varies across studies, particularly between those where patients knew they were receiving the active medication (open-label) and those where blinding was successfully maintained. Follow-up durations were limited in many initial trials, and this means the research provides limited insight into very long-term outcomes, highlighting where more research is needed to provide a more complete understanding.

Key Studies & References

  1. Disulfiram for the treatment of alcohol use disorder: A systematic review and meta-analysis of controlled trials
  2. Disulfiram: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Refusal (FAQ)


Q: Is Refusal the same kind of medicine as [similar-sounding drug]?

Refusal is classified in official documents as an Aldehyde Dehydrogenase Inhibitor. This means its mechanism works by disrupting the body’s processing of alcohol. Other medicines used for alcohol abstinence may belong to different pharmacological classes, such as opioid antagonists, which operate through different systems.


Q: Can Refusal affect my ability to drive or operate machinery?

Official labeling documents state that Refusal can potentially cause side effects such as drowsiness or fatigue. Regulatory warnings indicate that potential effects on mental alertness should be considered before driving or operating heavy machinery.


Q: Does Refusal have a 'Black Box Warning' from the FDA?

The official U.S. regulatory documents do not list a 'Black Box Warning' for this medication. However, the label contains prominent warnings about the risks of severe Hepatotoxicity (liver damage) and the potentially dangerous Disulfiram-Alcohol Reaction (DAR), which is mandatory safety information.


Q: Is it okay to take Refusal if I have high blood pressure?

Regulatory documents advise that the medicine be used with caution in patients with conditions like severe myocardial disease. The potential for a Disulfiram-Alcohol Reaction (DAR) to cause significant cardiovascular changes, such as low blood pressure (hypotension), requires caution in patients with pre-existing heart conditions.


Q: Does Refusal affect sleep patterns?

Drowsiness and fatigue are both listed in official product information as potential side effects, particularly when starting treatment. Insomnia (difficulty sleeping) has also been reported as a less common symptom in some patients.


Q: If I have a mild side effect from Refusal, should I keep taking it?

Official documents describe that some mild side effects, such as a metallic aftertaste or mild drowsiness, are often transient and may lessen with continued, consistent use. Decisions about continuing or stopping the medication based on side effects are typically addressed by a healthcare provider.


Q: How quickly does Refusal start working after taking it?

The enzyme inhibition needed for the deterrent effect starts to develop within a few hours of the first dose. Regulatory information indicates that patients need to be alcohol-free for at least 12 hours before the first dose, which helps establish the deterrent effect.


Q: Can teenagers use Refusal?

Safety and effectiveness have generally not been established in pediatric patients, including children. Official regulatory labeling does not provide a specific indication for use in this age group and often advises against it.


Q: Are there specific foods or drinks I should avoid while using Refusal?

Official labeling requires patients to strictly avoid all forms of alcohol. This restriction includes alcohol that may be disguised in certain foods, such as vinegars and extracts, and alcohol found in non-beverage products like cough mixtures and aftershave lotions.


Q: How long does the effect of one dose of Refusal typically last?

The drug’s enzyme-blocking effect is long-lasting and persists after the medicine is metabolized. Regulatory documents warn that the severe reaction to alcohol may occur for up to 14 days after the last dose of the medicine is taken, highlighting the extended persistence of the chemical deterrent.


Q: Can Refusal be taken with cold and flu medicine?

Because many cold and flu medicines contain ethanol (alcohol), they fall under the general regulatory restriction due to the risk of the severe Disulfiram-Alcohol Reaction (DAR). Official product information advises checking the ingredients of all over-the-counter products for alcohol content.


Q: Is it normal to feel a mild headache when starting Refusal?

Headache is listed in official documents as one of the side effects that can be experienced. It is sometimes described as a transient effect, meaning it may occur primarily during the first few weeks of starting treatment.


Q: What if I take Refusal and feel no difference?

Refusal is not designed to create a noticeable effect in the absence of alcohol. Its primary pharmacological action, the severe and unpleasant reaction, is strictly conditional upon the subsequent consumption of alcohol. If no alcohol is ingested, no deterrent reaction will be experienced.


Q: Are there any known severe allergic reaction signs to watch out for with Refusal?

Official documents list known hypersensitivity to the drug as a contraindication. The label notes that severe allergic reactions are possible, and less severe reactions like skin eruptions and dermatitis have also been reported.


Q: Do I need to take Refusal at the exact same time every day?

The drug is typically prescribed to be taken once daily to maintain continuous enzyme inhibition. Official documents state it may be taken in the morning or at bedtime if a patient experiences drowsiness, confirming that the time of day can be adjusted by a provider.


Q: How does Refusal compare to other treatments for the same condition, generally?

Refusal is described in authoritative sources as one of the FDA-approved pharmacological options to aid in maintaining alcohol abstinence. It functions as a chemical deterrent, which is distinguished from other FDA-approved medicines for alcohol use disorder that primarily work through mechanisms intended to reduce craving.


Q: Is Refusal habit-forming or addictive?

Authoritative clinical information describes the medicine as not causing physical dependence or drug tolerance. For this reason, it is not classified as a controlled substance in the U.S.


Q: What is the maximum amount of time someone has been studied taking Refusal?

Regulatory documents indicate that the treatment is intended to be long-term. While clinical trials have focused primarily on shorter periods, some research syntheses include data points extending up to 12 months of continuous use.


Q: Can children be prescribed Refusal?

Official U.S. regulatory documents state that the safety and effectiveness have not been established in pediatric patients. Use is generally not recommended in children.


Q: Does Refusal lose effectiveness over time?

Clinical information suggests that the body does not build a tolerance to the pharmacological effects of the drug. The enzyme-blocking action remains consistent for as long as the medicine is taken as directed.


Q: Is Refusal a drug that affects hormones?

The most common reported effect related to the endocrine system in males is decreased sexual ability (impotence). Official labeling does not provide a general statement regarding effects on all hormones.


Q: Can I buy Refusal online without a consultation?

Refusal is classified as a prescription-only medication. This status mandates that the drug be dispensed only upon the valid prescription and direct supervision of a licensed healthcare provider.


Q: Is there a maximum age limit for using Refusal?

Official regulatory documents do not list a maximum age limit for using the medicine. However, they advise that dose selection should be cautious for older adults, often suggesting starting at the lower end of the recommended range.

How should Refusal be stored and disposed of?

How to Store and Dispose of Refusal (Disulfiram)

Official regulatory labeling dictates specific conditions for storing and discarding Disulfiram tablets to maintain stability and ensure safety.

Required Storage and Protection

The medication must be stored at Controlled Room Temperature, typically between 20 C and 25 C. The tablets require protection from both light and excess moisture and must not be frozen or stored in areas of high humidity. To maintain product integrity, the medicine must be kept in its original container with the lid tightly closed.

Disposal and Child Safety

It is a mandatory requirement to keep Refusal tablets out of the sight and reach of children by storing them securely. Unused or expired medication must not be thrown away with household trash or wastewater. Disposal must follow special regulatory methods, such as utilizing a formal medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Refusal found in:

A-Z Index: